UPDATED May 22, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
VCTR | US$52.61 | 0.9% | 70.6% | US$3.4b | US$51.50 | PE15.5x | E30.6% | 2.8% | Diversified Financials | ||
BMRN | US$76.45 | -4.9% | -15.6% | US$14.7b | US$109.32 | PE70.7x | E29.8% | n/a | Pharmaceuticals & Biotech | ||
ORRF | US$26.82 | 0.2% | 43.4% | US$287.3m | US$31.33 | PB1.1x | E55.9% | 3.0% | Banks | ||
ENFN | US$9.31 | -3.4% | 19.4% | US$1.2b | US$9.82 | PE425.9x | E99.0% | n/a | Software | ||
CDXC | US$3.17 | -12.7% | 111.3% | US$238.6m | US$6.34 | PS2.9x | E99.5% | n/a | Pharmaceuticals & Biotech | ||
CLSK | US$18.44 | 7.7% | 312.5% | US$4.2b | US$23.33 | PE63.9x | E17.0% | n/a | Software | ||
APP | US$80.00 | -4.8% | 227.5% | US$27.6b | US$93.24 | PE44.3x | E24.7% | n/a | Software | ||
PWFL | US$5.24 | -4.7% | 76.4% | US$583.9m | US$8.43 | PS4.2x | E117.6% | n/a | Tech | ||
WEX | US$194.88 | -4.3% | 15.0% | US$8.1b | US$254.85 | PE30.9x | E30.5% | n/a | Diversified Financials | ||
CRC | US$47.39 | -2.5% | 17.8% | US$3.3b | US$63.00 | PE12.8x | E33.8% | 2.6% | Energy | ||
HNVR | US$16.57 | 0.4% | -7.2% | US$120.1m | US$18.50 | PB0.6x | E20.9% | 2.4% | Banks | ||
USCB | US$12.15 | -0.9% | 24.6% | US$238.8m | US$13.50 | PB1.2x | E25.3% | 1.6% | Banks | ||
HQY | US$79.46 | 4.8% | 39.8% | US$6.9b | US$100.00 | PE124.1x | E41.4% | n/a | Healthcare | ||
PACS | US$27.66 | -2.4% | n/a | US$4.2b | US$31.67 | PE33.9x | E31.3% | 0% | Healthcare | ||
AFYA | US$18.60 | -2.3% | 57.0% | US$1.7b | US$23.19 | PE17.7x | E22.6% | n/a | Consumer Services | ||
SIGI | US$97.27 | 1.3% | -2.7% | US$5.9b | US$106.43 | PE17.1x | E23.1% | 1.4% | Insurance | ||
HOLI | US$22.17 | -5.3% | 38.6% | US$1.4b | US$24.25 | PE18.3x | E28.5% | 0% | Tech | ||
BGNE | US$167.92 | 1.8% | -29.0% | US$17.5b | US$267.01 | PS6.4x | E60.6% | n/a | Pharmaceuticals & Biotech | ||
TLRY | US$1.86 | -10.1% | -23.1% | US$1.6b | US$2.37 | PS2.1x | E86.8% | n/a | Pharmaceuticals & Biotech | ||
HBIO | US$3.30 | -4.3% | -41.9% | US$142.0m | US$7.00 | PS1.3x | E106.7% | n/a | Pharmaceuticals & Biotech | ||
ODD | US$37.28 | -14.7% | n/a | US$2.2b | US$52.29 | PE29.5x | E18.6% | n/a | Household | ||
HTCR | US$0.75 | -9.2% | -60.2% | US$15.6m | US$3.00 | PB3x | E145.6% | 10.7% | Software | ||
IBTA | US$104.00 | -1.9% | n/a | US$3.2b | US$120.86 | PE82.8x | E46.6% | n/a | Media | ||
TRU | US$77.13 | -3.8% | 7.6% | US$14.9b | US$89.84 | PS3.8x | E47.3% | 0.5% | Commercial Services |